Lambertenghi-Deliliers G, Maiolo A T, Annaloro C, Pogliani E, Baldini L, Polli E
Cancer. 1984 Jul 15;54(2):199-201. doi: 10.1002/1097-0142(19840715)54:2<199::aid-cncr2820540203>3.0.co;2-v.
Prolymphocytic leukemia (PL) is a morphologically distinct disease generally characterized by unsatisfactory therapeutic response and brief survival. Aggressive chemotherapy protocols including doxorubicin (DX) have been successfully used as alternatives to treatments usually effective in chronic lymphocytic leukemia (CLL). A patient with typical PL, resistant to regimens containing DX, was treated with 4-demethoxydaunorubicin (4-dm DNR), a new anthracycline analog derived from daunorubicin (DNR). The therapeutic response was rapid and impressive; furthermore 4-dm DNR combined with arabinosyl cytosine (Ara-C) produced a complete remission which is unusual in PL.
幼淋巴细胞白血病（PL）是一种形态学上独特的疾病，通常具有治疗反应不佳和生存期短的特点。包括阿霉素（DX）在内的积极化疗方案已成功用作通常对慢性淋巴细胞白血病（CLL）有效的治疗方法的替代方案。一名典型的PL患者，对含DX的方案耐药，接受了4-去甲氧基柔红霉素（4-dm DNR）治疗，4-dm DNR是一种从柔红霉素（DNR）衍生而来的新型蒽环类类似物。治疗反应迅速且显著；此外，4-dm DNR与阿糖胞苷（Ara-C）联合使用产生了完全缓解，这在PL中并不常见。
